PCSK9	B:C1426592
genetic	B:C0678941
variants	I:C0678941
and	O
risk	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
:	O
a	O
mendelian	B:C2718019
randomisation	I:C2718019
study	I:C2718019
.	O

Statin	B:C0360714
treatment	B:C0087111
and	O
variants	B:C0678941
in	I:C0678941
the	I:C0678941
gene	I:C0678941
encoding	O
HMG	B:C0020374
-	I:C0020374
CoA	I:C0020374
reductase	I:C0020374
are	O
associated	O
with	O
reductions	O
in	O
both	O
the	O
concentration	O
of	O
LDL	B:C0023824
cholesterol	I:C0023824
and	O
the	O
risk	O
of	O
coronary	B:C0010068
heart	I:C0010068
disease	I:C0010068
,	O
but	O
also	O
with	O
modest	O
hyperglycaemia	B:C0020456
,	O
increased	B:C0043094
bodyweight	I:C0043094
,	O
and	O
modestly	O
increased	O
risk	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
,	O
which	O
in	O
no	O
way	O
offsets	O
their	O
substantial	O
benefits	O
.	O

We	O
sought	O
to	O
investigate	O
the	O
associations	O
of	O
LDL	B:C0023824
cholesterol	I:C0023824
-	O
lowering	O
PCSK9	B:C1426592
variants	B:C0678941
with	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
and	O
related	O
biomarkers	B:C0005516
to	O
gauge	O
the	O
likely	O
effects	O
of	O
PCSK9	B:C4051515
inhibitors	I:C4051515
on	O
diabetes	O
risk	O
.	O

In	O
this	O
mendelian	B:C2718019
randomisation	I:C2718019
study	I:C2718019
,	O
we	O
used	O
data	O
from	O
cohort	O
studies	O
,	O
randomised	B:C0206035
controlled	I:C0206035
trials	I:C0206035
,	O
case	B:C0007328
control	I:C0007328
studies	I:C0007328
,	O
and	O
genetic	O
consortia	O
to	O
estimate	O
associations	O
of	O
PCSK9	B:C1426592
genetic	B:C0678941
variants	I:C0678941
with	O
LDL	B:C0023824
cholesterol	I:C0023824
,	O
fasting	B:C1261430
blood	I:C1261430
glucose	I:C1261430
,	O
HbA1	B:C0019018
c	I:C0019018
,	O
fasting	B:C0015663
insulin	B:C0021641
,	O
bodyweight	O
,	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
,	O
BMI	B:C1305855
,	O
and	O
risk	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
,	O
using	O
a	O
standardised	B:C0936012
analysis	I:C0936012
plan	I:C0936012
,	O
meta-	B:C0920317
analyses	I:C0920317
,	O
and	O
weighted	O
gene	O
-	O
centric	O
scores	O
.	O

Data	O
were	O
available	O
for	O
more	O
than	O
550	O
000	O
individuals	B:C0237401
and	O
51	O
623	O
cases	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
.	O

Combined	B:C0936012
analyses	I:C0936012
of	O
four	O
independent	O
PCSK9	B:C1426592
variants	B:C0678941
(	O
rs11583680	B:C0678941
,	O
rs11591147	B:C0678941
,	O
rs2479409	B:C0678941
,	O
and	O
rs11206510	B:C0678941
)	O
scaled	O
to	O
1	O
mmol	O
/	O
L	O
lower	O
LDL	B:C0023824
cholesterol	I:C0023824
showed	O
associations	O
with	O
increased	B:C0920108
fasting	I:C0920108
glucose	I:C0920108
(	O
0·09	O
mmol	O
/	O
L	O
,	O
95	O
%	O
CI	O
0·02	O
to	O
0·15	O
)	O
,	O
bodyweight	O
(	O
1·03	O
kg	O
,	O
0·24	O
to	O
1·82	O
)	O
,	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
(	O
0·006	O
,	O
0·003	O
to	O
0·010	O
)	O
,	O
and	O
an	O
odds	O
ratio	O
for	O
type	O
diabetes	B:C0011847
of	O
1·29	O
(	O
1·11	O
to	O
1·50	O
)	O
.	O

Based	O
on	O
the	O
collected	O
data	O
,	O
we	O
did	O
not	O
identify	O
associations	O
with	O
HbA1c	B:C0019018
(	O
0·03	O
%	O
,	O
-	O
0·01	O
to	O
0·08	O
)	O
,	O
fasting	B:C0015663
insulin	B:C0021641
(	O
0·00	O
%	O
,	O
-	O
0·06	O
to	O
0·07	O
)	O
,	O
and	O
BMI	B:C1305855
(	O
0·11	O
kg	O
/	O
m	O
(	O
2	O
)	O
,	O
-	O
0·09	O
to	O
0·30	O
)	O
.	O

PCSK9	B:C1426592
variants	B:C0678941
associated	O
with	O
lower	O
LDL	B:C0023824
cholesterol	I:C0023824
were	O
also	O
associated	O
with	O
circulating	O
higher	B:C0920108
fasting	I:C0920108
glucose	I:C0920108
concentration	O
,	O
bodyweight	O
,	O
and	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
,	O
and	O
an	O
increased	O
risk	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
.	O

In	O
trials	B:C0008976
of	O
PCSK9	B:C4051515
inhibitor	I:C4051515
drugs	B:C0013227
,	O
investigators	B:C0035173
should	O
carefully	O
assess	O
these	O
safety	O
outcomes	O
and	O
quantify	O
the	O
risks	O
and	O
benefits	O
of	O
PCSK9	B:C4051515
inhibitor	I:C4051515
treatment	B:C0087111
,	O
as	O
was	O
previously	O
done	O
for	O
statins	B:C0360714
.	O

British	B:C0016617
Heart	I:C0016617
Foundation	I:C0016617
,	O
and	O
University	B:C0035172
College	I:C0035172
London	I:C0035172
Hospitals	I:C0035172
NHS	I:C0035172
Foundation	I:C0035172
Trust	I:C0035172
(	O
UCLH	B:C0035172
)	O
National	B:C0035172
Institute	I:C0035172
for	I:C0035172
Health	I:C0035172
Research	I:C0035172
(	I:C0035172
NIHR	I:C0035172
)	I:C0035172
Biomedical	I:C0035172
Research	I:C0035172
Centre	I:C0035172
.	O

